Holen Sie sich die Stockscreener-App
34.37
3.99%
-1.43
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities - GlobeNewswire
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - ulpravda.ru
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - ulpravda.ru
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock near bottom after declineAnalyst Upgrade & Verified Chart Pattern Signals - ulpravda.ru
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from strong economy2025 Historical Comparison & Community Consensus Stock Picks - ulpravda.ru
What dividend safety score for NewAmsterdam Pharma Company N.V. stock2025 Technical Patterns & Low Risk High Reward Ideas - ulpravda.ru
Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthEconomic Indicators Overview & Affordable Growth Investments - ulpravda.ru
A Look At NewAmsterdam Pharma (NAMS) Valuation As Late Stage CETP Trial Progress Draws Investor Attention - Sahm
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 - Insider Monkey
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners - Investing.com Nigeria
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4%Time to Sell? - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS - TechStock²
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Behavioral Patterns of NAMS and Institutional Flows - Stock Traders Daily
ID Info Business Services Limited Enters Reversal Setup in Weekly ChartsEconomic Indicators Overview & Target Triple-Digit Stock Opportunities - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 75,117 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock - MarketBeat
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
How (NAMSW) Movements Inform Risk Allocation Models - Stock Traders Daily
Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - Early Times
EBITDA per share of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView — Track All Markets
Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketMarket Growth Report & Short-Term Trading Alerts - Улправда
Analyst Downgrade: Will Lee Enterprises Incorporated LE70 stock keep raising dividendsJuly 2025 Big Picture & Precise Buy Zone Identification - moha.gov.vn
How NewAmsterdam Pharma Company N.V. Equity Warrant stock trades before earningsWeekly Investment Summary & Verified Swing Trading Watchlist - Улправда
Will NewAmsterdam Pharma Company N.V. stock deliver strong dividend growthEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterQuarterly Profit Report & Real-Time Volume Spike Alerts - Улправда
Aug Selloffs: Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Is NewAmsterdam Pharma Company N.V. stock in correction or buying zone2025 Sector Review & Reliable Breakout Forecasts - Улправда
Is NewAmsterdam Pharma Company N.V. stock undervalued vs historical averagesJuly 2025 Technicals & Daily Stock Trend Reports - DonanımHaber
Will NewAmsterdam Pharma Company N.V. stock outperform tech sector in 20252025 Earnings Surprises & Community Trade Idea Sharing - DonanımHaber
Why NewAmsterdam Pharma Company N.V. stock attracts global investorsOptions Play & Real-Time Sentiment Analysis - DonanımHaber
Will NewAmsterdam Pharma Company N.V. stock beat EPS estimatesPortfolio Gains Report & Real-Time Stock Entry Alerts - ulpravda.ru
NewAmsterdam Pharma (NASDAQ:NAMS) Given New $50.00 Price Target at Stifel Nicolaus - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Understanding Momentum Shifts in (NAMSW) - Stock Traders Daily
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? - Yahoo Finance
Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by Maverick Capital Ltd. - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Price-Driven Insight from (NAMS) for Rule-Based Strategy - Stock Traders Daily
It is Poised to be a Bull Market for NewAmsterdam Pharma Company NV (NAMS) - setenews.com
Stempoint Capital LP Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):